UBE2D2

Across TCGA pan-cancer cohorts, UBE2D2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated UBE2D2 data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher UBE2D2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated UBE2D2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where UBE2D2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.262	0.984	.038	6	view →
CCRCC	DFS	Quartile	All	0.785	0.975	.038	4	view →
LSCC	DFS	Median	II,III,IV	1.000	0.774	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

UBE2D2–PDAC (OS)

Open the PDAC breakdown →